Wednesday, 26 August 2026European Markets

FORFARMERS Stock Bearish By 9% So Far On Thursday

Loading stream...

(VIANEWS) - Shares of FORFARMERS (AEX-Index: FFARM.AS) slid 9.43% to €2.69 at 11:07 EST on Thursday, after four consecutive sessions in a row of gains. AEX-Index is falling 0.41% to €741.16, after two sequential sessions in a row of losses. This seems, so far, a somewhat negative trend trading session today.

FORFARMERS's last close was €2.98, 12.61% under its 52-week high of €3.41.

About FORFARMERS

ForFarmers N.V. provides feed solutions for conventional and organic livestock farming in the Netherlands, Belgium, Germany, Poland, and the United Kingdom. It offers compound feed and blends, feed for young animals and specialties, raw materials and coproducts, seeds, and fertilizers. The company is involved in production and delivery of feed, as well as engaged in logistics services. ForFarmers N.V. was founded in 1896 and is headquartered in Lochem, the Netherlands.

Earnings Per Share

As for profitability, FORFARMERS has a trailing twelve months EPS of €0.2.

PE Ratio

FORFARMERS has a trailing twelve months price to earnings ratio of 13.45. Meaning, the purchaser of the share is investing €13.45 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.12%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 17, 2023, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 6.96%.

More news about FORFARMERS (FFARM.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com